Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...

MetaVia (MTVA) reported additional top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between ...

Doctors have explained the potential pros and cons of these so-called 'skinny jabs', with everything from nausea to abdominal ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...

College of Charleston's Kindred Hurtado examines one woman's weight-loss journey with the assistance of semaglutides.

New study finds potential link between GLP1 agonists and depression, urging further investigation into patient safety.

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...

Discover more ways to keep your body and mind healthy and strong against dementia.

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...